• Narimova Gulchekhra Dzhumaniyazovna
  • Ergashova Shakhnoza Erkinovna


Cushing's syndrome, steroid diabetes, insulin resistance


Impaired glucose metabolism in patients with Cushing syndrome is due to a combination of several concomitant glucocorticoid-related effects that directly or indirectly affect glucose homeostasis, mainly by inducing gluconeogenesis and impaired insulin receptor signaling. Complex interactions between genetic predisposing factors, aging, altered insulin sensitivity, and β cell function contribute to the development, progression, and HA of induced glucose metabolism abnormalities. In this regard, the purpose of this study was to study the violation of carbohydrate metabolism of patients with Cushing syndrome depending on the duration of hypercortisolemia and the activity of the disease.


Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40:479–84.

Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism? Eur J Endocrinol 2014; 170:311–19.

Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2010 95 3309–3317. (doi:10.1210/jc.2010-0119).

Hassan-Smith ZK, Sherlock M, Reulen RC, et al. Outcome of Cushing’s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 2012; 97:1194–201.

Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB. Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab2013; 98:1022–30.

Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 768–777. (doi:10.1111/j.1365-2265.2004.02168.x).

Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends in Endocrinology and Metabolism 2011 22 499–506. (doi:10.1016/j.tem.2011.09.001).

D.D Maksudov, F.I. Musurmanov, A.I. Khasanov, B.D. Pulatova. Development of a comprehensive programme for the comprehensive treatment of patients with maxillofacial phlegmon with viral hepatitis B // novateur publications. JournaINX- A multidisciplinary Peer Reviewed Journal ISSN No: 2581 - 4230 Feb. -2021. VOLUME 7, ISSUE 2, Page 191-198.

Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013; 169:715–23.

Santos A, Resmini E, Gómez-Ansón B, Crespo I, Granell E, Valassi E, et al. Cardiovascular risk and white matter lesions after endocrine control of Cushing’s syndrome. Eur J Endocrinol. (2015) 173:765–75.doi: 10.1530/EJE-15-0600

Trementino L, Appolloni G, Concettoni C, Cardinaletti M, Boscaro M, Arnaldi G. Associatio n of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome.European Journal of Endocrinology 2012 166 35–42. (doi:10.1530/EJE-11-0722).

Valassi E, Crespo I, Keevil BG, Aulinas A, Urgell E, Santos A, et al. Affective alterations in patients with Cushing’s syndrome in remission are associatedwith decreased BDNF and cortisone levels. Eur J Endocrinol. (2017) 176:221–31. doi: 10.1530/EJE-16-0779

Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM; ERCUSYN Study Group: The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011; 165:383–392

van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schaap J, Nassander UK, Heine RJ, Mari A, Dokter WH, Diamant M. Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men. European Journal of Endocrinology 2010 162 729–735. (doi:10.1530/EJE-09-1034).

Yaneva M, Kalinov K, Zacharieva S. Mortality in Cushing’s syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol 2013; 169:621–27.

Yi CX, Foppen E, Abplanalp W, Gao Y, Alkemade A, laFleur SE, Serlie MJ, Fliers E, Buijs RM, Tschop MH et al.. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes 2012 61 339–345. (doi:10.2337/db11-1239).